BioPharma Dive: A 21st century diabetes option: Will Oramed be first to market with oral insulin?

Josh Hexter, Oramed’s COO, spoke with BioPharma Dive about Oramed’s product and progress.
“Our oral insulin is not a substitute for insulin injections, but rather a new, earlier treatment option.”

http://www.biopharmadive.com/news/a-21st-century-diabetes-option-will-oramed-be-first-to-market-with-oral-in/402100/